Discover 1 curated intelligence briefings related to this specific topic.
Recent data from September 2026 reveals a seismic shift in oncology: multi-cancer early detection (MCED) tests are achieving unprecedented accuracy in Stage I and II cancers, moving liquid biopsies from the periphery of research to the center of clinical practice.
